CLINICAL TRIALS PROFILE FOR EPLERENONE
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Eplerenone
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00082589 ↗ | The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure | Completed | Pfizer | Phase 4 | 2004-04-01 | The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure |
NCT00082589 ↗ | The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | 2004-04-01 | The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure |
NCT00094302 ↗ | Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 2006-08-01 | The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function. |
NCT00094302 ↗ | Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function | Completed | HealthCore-NERI | Phase 3 | 2006-08-01 | The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function. |
NCT00094302 ↗ | Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function | Completed | New England Research Institutes | Phase 3 | 2006-08-01 | The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function. |
NCT00108251 ↗ | Aldosterone Antagonism in Diastolic Heart Failure | Completed | US Department of Veterans Affairs | Phase 4 | 2004-08-01 | The primary purpose of this study is to determine whether eplerenone has a beneficial effect on improving exercise ability in patients with diastolic heart failure. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Eplerenone
Condition Name
Clinical Trial Locations for Eplerenone
Trials by Country
Clinical Trial Progress for Eplerenone
Clinical Trial Phase
Clinical Trial Sponsors for Eplerenone
Sponsor Name